Tag - NVAX

Allos Therapeutics Inc. (Nasdaq:ALTH), Amedisys Inc. (Nasdaq:AMED) and Novavax Inc. (Nasdaq:NVAX) are among the most actively traded companies in Thursday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Vical Inc. (Nasdaq:VICL), China Natural Gas Inc. (Nasdaq:CHNG), Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI), Sequenom Inc. (Nasdaq:SQNM), Century Aluminum Co. (Nasdaq:CENX) and Sanmina-SCI Corp. (Nasdaq:SANMD).

SeaChange International Inc. (Nasdaq:SEAC), CPI Corp. (Nasdaq:CPY) and Sinovac Biotech Ltd. (Nasdaq:SVA) are among the biggest percentage losers in Wednesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Novavax Inc. (Nasdaq:NVAX), Trubion Pharmaceuticals Inc. (Nasdaq:TRBN), Zion Oil and Gas Inc. (Nasdaq:ZN), Applied Signal Technology Inc. (Nasdaq:APSG), Hardinge Brothers Inc. (Nasdaq:HDNG) and Blyth Inc. (Nasdaq:BTH).

Novavax Inc. (Nasdaq:NVAX), ADC Telecommunications Inc. (Nasdaq:ADCT) and Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI) are among the most actively traded companies in Wednesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Sequenom Inc. (Nasdaq:SQNM), ImmunoGen Inc. (Nasdaq:IMGN), Ticketmaster Entertainment Inc. (Nasdaq:TKTM), GeoResources Inc. (Nasdaq:GEOI), Zion Oild and Gas Inc. (Nasdaq:ZN) and Biocryst Pharmaceuticals Inc. (Nasdaq:BCRX).

Alpha Pro Tech Ltd. (Nasdaq:APT), BofI Holding Inc. (Nasdaq:BOFI) and Novavax Inc. (Nasdaq:NVAX) are among the new 52-week highs in Tuesday's trading among companies with market capitalizations under $1 billion.

Novavax Inc. (Nasdaq:NVAX), Brigham Exploration Co. (Nasdaq:BEXP) and America's Car-Mart Inc. (Nasdaq:CRMT) are among the biggest percentage gainers in Tuesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Alpha Pro Tech Ltd. (Nasdaq:APT), Sinovac Biotech Ltd. (Nasdaq:SVA), NB&T Financial Group Inc. (Nasdaq:NBTF), Ardea Biosciences Inc. (Nasdaq:RDEA), American Physicians Capital Inc. (Nasdaq:ACAP) and BTU International Inc. (Nasdaq:BTUI).

Novavax Inc. (Nasdaq:NVAX), Sequenom Inc. (Nasdaq:SQNM) and Biocryst Pharmaceuticals Inc. (Nasdaq:BCRX) are among the most actively traded companies in Tuesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI), China Medical Technologies Inc. (Nasdaq:CMED), CardioNet Inc. (Nasdaq:BEAT), Immunomedics Inc. (Nasdaq:IMMU), Brigham Exploration Co. (Nasdaq:BEXP) and Savient Pharmaceuticals Inc. (Nasdaq:SVNT).

Novavax Inc. (Nasdaq:NVAX), Trubion Pharmaceuticals Inc. (Nasdaq:TRBN) and Immunomedics Inc. (Nasdaq:IMMU) are among the most actively traded companies in Monday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Century Aluminum Co. (Nasdaq:CENX), POZEN Inc. (Nasdaq:POZN), AgFeed Industries Inc. (Nasdaq:FEED), Sequenom Inc. (Nasdaq:SQNM), Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI) and Encore Wire Corp. (Nasdaq:WIRE).

Allos Therapeutics Inc. (Nasdaq:ALTH), Novavax Inc. (Nasdaq:NVAX) and OmniVision Technologies Inc.(Nasdaq:OVTI) are among the most actively traded companies in Friday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Immunomedics Inc. (Nasdaq:IMMU), Aruba Networks Inc. (Nasdaq:ARUN), Sequenom Inc. (Nasdaq:SQNM), Century Aluminum Co. (Nasdaq:CENX), Solarfun Power Holdings Co Ltd. (Nasdaq:SOLF) and Canadian Solar Inc. (Nasdaq:CSIQ).

ICT Group Inc. (Nasdaq:ICTG), Novavax Inc. (Nasdaq:NVAX) and Books-A-Million Inc. (Nasdaq:BAMM) are among the new 52-week highs in Wednesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Bon-Ton Stores Inc. (Nasdaq:BONT), Sinovac Biotech Ltd. (Nasdaq:SVA), FirstCity Financial Corp. (Nasdaq:FCFC), Atlantic Tele-Network Inc. (Nasdaq:ATNI), American Realty Investors Inc. (Nasdaq:ARL) and Nektar Therapeutics (Nasdaq:NKTR).

Nymox Pharmaceutical Corporation (Nasdaq:NYMX), CardioNet Inc (Nasdaq:BEAT) and Bon-Ton Stores Inc (Nasdaq:BONT) are among the biggest percentage gainers in Wednesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Novavax Inc (Nasdaq:NVAX), Blue Coat Systems Inc (Nasdaq:BCSI), Sequenom Inc (Nasdaq:SQNM), Hovnanian Enterprises Inc (Nasdaq:HOV), First Bancshares Inc (Nasdaq:FBSI) and ICT Group Inc (Nasdaq:ICTG).

Matrixx Initiatives (Nasdaq:MTXX), Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI) and Canadian Solar Inc. (Nasdaq:CSIQ) are among the most actively traded companies in Wednesday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Huron Consulting Group Inc. (Nasdaq:HURN), Kirklands Inc. (Nasdaq:KIRK), Sequenom Inc. (Nasdaq:SQNM), Novavax Inc. (Nasdaq:NVAX), Biocryst Pharmaceuticals Inc. (Nasdaq:BCRX) and UAL Corp. (Nasdaq:UAUA).

Canadian Solar Inc. (Nasdaq:CSIQ), EnerNOC Inc. (Nasdaq:ENOC) and Orthovita Inc. (Nasdaq:VITA) are among the most actively traded companies in Thursday's trading among companies with market capitalizations under $1 billion.

Also included among the results: Columbia Banking System Inc. (Nasdaq:COLB), Novavax Inc. (Nasdaq:NVAX), CardioNet Inc. (Nasdaq:BEAT), JA Solar Holdings Co Ltd. (Nasdaq:JASO), UAL Corp. (Nasdaq:UAUA) and Sequenom Inc. (Nasdaq:SQNM).

Stocks reversed early gains today as the second quarter comes to a close with more of a whimper than a bang. Jobless rates remain high in major metropolitan areas with the Labor Department reporting today that rates rose for this past May against the year ago same period in all 372 metropolitan areas that it tracks. Areas hit hardest include those with major manufacturing centers that feed into housing construction. While overall U.S. unemployment climbed to 9.4 percent in May, hardest hit is El Centro, California with a 26.8 percent rate. |

Consumer Confidence Report numbers, as reported by the Conference Board, further the fear on Wall Street as investors had expected the numbers to hold steady from April and May gains, however the index for June stands at just 49.3, down from 54.8 in May.

All of the major U.S. markets were down today with the Dow closing at 8,448, the Nasdaq trimmed by half a percent to 1,835, and the S&P 500 giving up 8 points to close at 919.

The Russell 2000, a composite index of the 2,000 largest small-cap stocks, closed down today at 501, for a loss of 1 percent.

Bright spots among small-cap stocks were lead by Annapolis Bancorp (Nasdaq:ANNB) up 38% to close the day at $3.80; Novavax (Nasdaq:NVAX) up 31% on news that Spanish pharmaceutical company Rovi will use Novavax's "Virus Like Particle" technology in the development of a vaccine for H1N1, also known as "swine flu"; LightPath Technologies (Nasdaq:LPTH) up 27%; Plumas Bancorp (Nasdaq:PLBC) up 25%; and Jacksonville Bancorp (Nasdaq:JXSB) up 23%.

While small-cap financial showed leadership today, large cap financial stocks like Bank of America (NYSE:BAC), Citigroup (NYSE:C), HSBC Holdings (NYSE:HBC), and Wells Fargo (NYSE:WFC) were down or up less than one-tenth of one percent.

The leader in small-cap price decliners was Cubic Energy (AMEX:QBC), down 30% on ongoing debt concerns with Wells Fargo Energy Capital. Cubic Energy was followed by Raser Technologies (NYSE:RZ), down 27%; Sunrise Senior Living (NYSE:SRZ), down 23%; and Northeast Bancorp (Nasdaq:NBN), down 21%.

*****If today had a lot going on then yesterday was downright boring. On Monday, around 10:30 AM, the S&P 500 rose above 924. By 12:30 PM, it rose to 927.99. Ignore the first hour of trading (when the S&P 500 made a comparatively wild 8-point swing), and the S&P 500 was confined to a 4-point range for 5 ½ hours.

Days like this make watching paint dry sound exciting. And as I'm typing this note, it's down about 1.3%.

And TradeMaster technical analyst Jason Cimpl tells me it could be like this all week as we head into a holiday weekend. If you want to catch a replay of his video that gives insights into this week's market direction just visit here. (or go to trademasterstocks.com/videoreport)

Great. But that's summer trading for you…

*****The Case-Shiller home price index, which measures home prices in 20 U.S. cities, showed that home prices fell 18.1% in April. And that was better than expected!

Of course, the index was only half a percentage point better, which most likely falls within the margin for error. Still, the results prompted the senior economist at Wachovia, Mark Vitner, to say "It is looking a bit better…[t]he largest declines are probably past."

And David Blitzer, chairman of the S&P index committee said, "While one month's data cannot determine if a turnaround has begun, it seems that some stabilization may be appearing in some of the regions…"

*****At first glance, these comments might seem a little, um, out of touch with reality. After all, how can anyone think that an 18% decline in home values is good?

The reason is that its foreclosure sales that are driving the Case-Shiller Index lower. Close to 5 million seized homes may be sold this year. To add some color, according to Bloomberg, 73% of all home and condo sales in Las Vegas in May were foreclosure re-sales.

73% -- that is an amazing number. And because these homes get sold at fire-sale prices, the affect on the overall housing market is dramatic.

*****That foreclosed homes are finding new owners is what's prompting economists to say prices may be stabilizing. And once prices stabilize, then the erosion of household wealth stops. And, then, maybe consumer spending picks up.

At least that's how the story goes...

There are some problems with this rosy scenario. Falling home and stock values claimed around $13.9 trillion in household wealth since 1997. That means there's a long way to go just to get back to break even. But with unemployment expected to persist above 7% for the next couple of years, where is the buying pressure for homes and the earnings power for public companies going to come from?

It's easy to imagine investors buying foreclosed property at discounted prices. But that doesn't mean the same level of demand exists for regular home sales. In fact, I'd go so far as to say there's no way demand for homes will be sustained beyond foreclosure sales.

*****Banks are taking losses as they clear bad mortgage loans from their books. That means banks will have room to make more loans - but will people want them?

Again, I suspect not.

That means banks will struggle to make up the losses and keep earnings growing. And with earnings season right around the corner (Alcoa (NYSE:AA) kicks earnings season off on July 7) investors should be on their toes.

P.S. A reader sent in an email yesterday asking about China and whether it's a good time to get back in. After last year's sell-off Chinese stocks are moving back up. If you missed the first China bull, this is your second chance. I've just finished a stock research report on 3 China-based stocks that every investor should have in his or her portfolio. Find out more here.

Biopharmaceutical company Novavax Inc. (Nasdaq: NVAX) today reported a third quarter net loss wider than last year and below analysts’ expectations on Wall Street.

For the three months ended Sept. 30, the Rockville, Md.-based company recorded a net loss of $9 million, or $0.15 per share, wider than the consensus of four analysts polled by Thomson that was for a net loss of $0.13 per share. The current quarter’s net widened from a $5 million net loss, or $0.08 per share, in the third quarter of 2006.

Revenues were $1.3 million, an increase of $0.1 million over the $1.2 million reported in the same quarter last year. Four analysts polled by Thomson were on average forecasting revenues of $0.83 million.

Novavax said revenues consisted of $0.5 million in sales and royalties from ESTRASORB paid by Esprit Pharma, Inc. and contract research and development revenues of $0.7 million. The small cap generated $0.6 million in research and development revenues in the third quarter of 2006. 

Shares of Novavax (NVAX) were halted in pre-market trading.

Biopharmaceutical company Novavax, Inc. (Nasdaq: NVAX) reported a net loss for the second-quarter, beating estimates by a penny.

For the three months ended June 30, the Rockville, Md.-based company reported a net loss of $8.2 million, or $0.13 loss per share, while three analysts polled by Thomson Financial were expecting a loss of $0.14 per share. This compares with a net loss of $6.4 million, $0.10 loss per share, in the second quarter of 2006.

Revenues for the second quarter were $0.2 million, falling short of the consensus of three analysts polled by Thomson Financial of $0.9 million. Revenues for the same period last year were $0.8 million.

The company also informed investors of major expected announcements for the second half of the year, including the announcement of two new vaccine candidates in late-stage discovery, pre-clinical results for its seasonal flu VLP vaccine candidates and interim results from the company’s Phase I/IIa pandemic flu vaccine trial.

Novavax was halted in pre-market trading.

Shares of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) are rising following news this morning that the Cambridge, Mass.-based company has entered into an alliance with Roche Holding Ltd., according to which Roche obtains a non-exclusive license to Alnylam’s technology platform for developing RNAi therapeutics. Alnylam will receive $331 million upfront. The agreement could be worth more than $1 billion when factoring in future milestone payments. RNAi is a natural mechanism that the body uses to inhibit expression of certain genes. Shares are up $9.19, or 60%, to $24.39.

Shares of Novavax Inc. (Nasdaq: NVAX) are rising following news this morning that the Rockville, Md.-based pharmaceutical company has signed a non-exclusive, worldwide license agreement with industry giant Wyeth (NYSE: WYE) to obtain rights to a patent application covering virus-like particle technology for use in human vaccines in certain fields of use. The stock is up $0.02, or 1%, to $3.07.

Known on Wall Street as Big Pharma, multibillion-dollar companies such as Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK) and Bristol-Myers Squibb Company (NYSE: BMY) dominate the prescription drug market. But a compelling argument can be made for investing in the biotechnology sector, since biotechs have consistently outperformed the pill companies for the past few years.

While Amgen Inc. (Nasdaq: AMGN) and Genentech Inc. (NYSE: DNA), biotech's biggest names, have fallen on hard times (Amgen's stock has plunged 26% from its January high while Genentech's shares are off 14%), some smaller biotech companies hold promise., some smaller biotech companies hold promise.

One such micro-cap is Antares Pharma, Inc. (AMEX: AIS), a $90 million specialized pharmaceutical company with patented drug delivery platforms including Advanced Transdermal Delivery gels (medications—hormones or other active ingredients—that are applied to the surface of the skin in gel form), reusable needle-free injection systems, disposable mini-needle injection systems and fast-melt oral tablets. In the face of direct competitive pressures from companies developing transdermal gels such as NexMed, Inc. (Nasdaq: NEXM), Bentley Pharmaceuticals, Inc. (NYSE: BNT) and Novavax, Inc. (Nasdaq: NVAX), and players like Bioject Medical Technologies Inc. (Nasdaq: BJCT), which produces needle-free injection systems, Antares has flourished.